As part of strategies to reposition its prestigious brands of over three decades, BCN Plc., one of Nigeria’s leading pharmaceutical manufacturing companies, recently organised a continuous medical education (CME) for its key products, Beecodeen, Nerve & Bone Liniment and Ivax Suspension.
Speaking with Pharmanews at the occasion, Mr Mustua Ali Ariwala, chief marketing officer of BCN Plc.(formerly Boots Company Nig. Limited), said Beecoden is a compound aspirin and a codeine tablet indicated for the relief of mild to moderate pain.
Containing anti-inflammatory and anti-pyretic properties, the drug, he explained, is particularly effective in the relief of headache, rheumatic and nerve pains, toothache and treatment of colds and feverish conditions.
Mr Ariwala also explained that Nerve & Bone Liniment is a valuable household embrocation for the treatment of rheumatic pains, strains, sprains, lumbago, stiffness and sciatica; while Ivax Suspension is a preparation for bacterial diarrhea. Ivax, he added, is for the treatment of both the cause and symptoms of bacterial indication of the intestinal tract.
The memorable event, chaired by Prof. E. M. Essien and attended by several health care professionals, was held at the Lagos Airport Hotel, Ikeja, Lagos.
Also at the event was Professor H.A.B. Coker, dean of the Faculty of Pharmacy, University of Lagos, who is also a technical director of the company. Prof. Coker delivered a lecture on pain management at the event.
Earlier in his welcome address, Mr Ahmed Yusuf Ahmed, the managing director/chief executive officer of BCN traced the history of the company to September 12, 1960, when The Boots Company (Nig.) Ltd was incorporated as a wholly owned subsidiary of the Boots Company Plc., Nottingham, England – one of Britain’s largest pharmaceutical companies with large international business and considerable investment in pharmaceutical research.
BCN, he said with its pharmaceutical manufacturing plant at Oregun Industial Estate, Ikeja, manufactures quality products that have stood the test of time, adding that the 30 years local manufacturing facility is tailored to meet present operations and the manufacture of new quality products.
The BCN boss disclosed that the company was ready to reinforce its position as a manufacturer of high quality products that have been tested and trusted for decades.
Ahmed added that the company is poised to expand its operations to tap the opportunities available in the pharmaceutical market.
He said that with Nigeria set to become the 8th most populous country in the world by 2050, and the strong demand for improved management of infectious diseases like HIV, TB, Malaria, as well as child mortality conditions, the Nigeria market size which is presently about 170 million is bound to increase.
He explained that because Nigeria also provides 60 per cent of health care products sold in the ECOWAS market of over 600 million people and the aggressive campaign against substandard drugs by NAFDAC, more opportunities now abound in the pharmaceutical market.
BCN, he said, will take advantage of the opportunity by making good use of its existing installed capacity, launching of its most valuable brands and make them available throughout the country.
The BCN helmsman also disclosed that the company is set to open new products lines in other therapeutic segments, strengthen and rebuild its marketing and distribution network to make sure its products are available whenever they are needed.The company, he said will also build a new state of the art manufacturing facility to meet future capacity requirement and WHO GMP standards.